Collegium Pharmaceutical (NASDAQ:COLL) Posts Quarterly Earnings Results, Beats Estimates By $0.24 EPS

by · The Cerbat Gem

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) released its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24, FiscalAI reports. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period in the previous year, the company posted $1.49 EPS. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year.

Here are the key takeaways from Collegium Pharmaceutical’s conference call:

  • AZSTARYS acquisition: Proposed cash purchase of $650M (plus up to $135M milestones) expected to close in Q2, which management says will be immediately accretive to adjusted EBITDA, deliver >$50M pro forma H2‑2026 revenue, >$50M cost synergies within 12 months, and extend portfolio patent protection through December 2037.
  • Jornay PM momentum: Prescriptions rose 14% YoY to >206k, net revenue was $38.9M (+36% YoY), prescribers hit ~30,000, and company projects Jornay revenue of $190M–$200M in 2026 (≈31% growth).
  • Pain portfolio and cash generation: Pain net revenue was $154.6M (+4% YoY) with BELBUCA and XTAMPZA ER growing, the company generated $57.1M cash from operations and ended Q1 with $421.8M cash to support business development, debt paydown, and share repurchases; 2026 guidance was reaffirmed.
  • Near-term risks: Hikma launched authorized generics of Nucynta/Nucynta ER (creating competitive pressure despite a profit‑share), and the AZSTARYS deal will be financed partly with a $300M term loan leaving pro forma net debt/adjusted EBITDA around ~2x, which introduces short‑term leverage and integration risk despite management’s expectation of rapid deleveraging.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock traded down $1.53 during midday trading on Friday, hitting $37.80. 697,981 shares of the company’s stock were exchanged, compared to its average volume of 507,405. Collegium Pharmaceutical has a 52-week low of $27.84 and a 52-week high of $50.79. The stock has a 50-day moving average price of $35.34 and a two-hundred day moving average price of $41.62. The company has a debt-to-equity ratio of 2.57, a quick ratio of 1.48 and a current ratio of 1.81. The company has a market cap of $1.23 billion, a P/E ratio of 18.53 and a beta of 0.76.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

Wall Street Analyst Weigh In

A number of analysts recently issued reports on COLL shares. Barclays decreased their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Check Out Our Latest Research Report on Collegium Pharmaceutical

Insider Activity

In related news, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after purchasing an additional 242,310 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Collegium Pharmaceutical by 237.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after purchasing an additional 225,679 shares in the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 854.2% in the 3rd quarter. Voloridge Investment Management LLC now owns 249,473 shares of the specialty pharmaceutical company’s stock worth $8,729,000 after purchasing an additional 223,329 shares in the last quarter.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Featured Stories